Navigating MFN Drug Pricing Reform
Scenario planning for International Reference Pricing (IRP)
A major policy shift is redefining U.S. drug pricing. The May 2025 U.S Executive Order may change how market access and pricing leaders define drug launch strategies now and in the future. With Most-Favored Nation (MFN) pricing potentially linking U.S. drug prices to international markets, market access teams need clarity to continue to optimise pricing and reimbursements strategies.
This comprehensive resource analyses potential scenarios and provides insights to help you prepare for an uncertain future.
Why download?
Strategic Clarity: Gain an understanding of the two MFN implementation scenarios and their portfolio impacts with data-driven analysis.
Launch Optimisation: Discover how strategic launch sequencing can provide up to 12% average price protection in MFN scenarios.
Risk Assessment: Evaluate patient savings potential and revenue impacts across medical and pharmacy benefit channels.
Future-Ready Strategy: Read commentary from our expert team, exploring the implications of each scenario.
What's inside?
Executive Order breakdown and legal challenge analysis
Cost impact analysis with cross-country price comparisons
Implications for consumer pathway and payer expectations
Actionable steps to mitigate risk and future-proof your pricing and launch strategies.
This Resource is Essential For: Market access directors, pricing strategists, and pharmaceutical executives preparing for IRP implementation. Particularly teams managing global launch strategies, portfolio optimisation, and regulatory compliance in the evolving U.S healthcare landscape.
Get Your Resource